IGF-1 fusion polypeptides and therapeutic uses thereof

Details for Australian Patent Application No. 2006203882 (hide)

International Classifications

Event Publications

19 July 2007 PCT application entered the National Phase

PCT publication WO2006/074390 Priority application(s): WO2006/074390

5 November 2009 Amendment Made

The nature of the amendment is: Amend the invention title to read IGF-1 fusion polypeptides and therapeutic uses thereof 2006222372 F. Hoffman-La Roche AG The nature of the amendment is: Amend the invention title to read 1-sulfonyl-piperdine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type II diabetes mellitus

12 May 2011 Application Accepted

Published as AU-B-2006203882

8 September 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.